A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease

Summary

This is a phase 3, multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an equal randomization among the Hemay005 high dose, lower dose and placebo treatment groups. After subject randomization, each subject will enter an core-treatment Phase for 12 weeks following an extended-treatment phase for another 40 weeks and a follow up phase for 4weeks.

Timeline

Start

2023-11-13

Primary completion

2026-05-30

Completion

2026-06-30

Drugs

Indications